Gene-based continuous expression of FVIIa for the treatment of hemophilia.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2741/269PMID 22202061
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The next step in gene delivery: molecular engineering of adeno-associated virus serotypes.

  2011cited by this paper
• Proprotein Convertases

  2011cited by this paper
• The expanding range of parvoviruses which infect humans

  2010cited by this paper
• Cost of care of haemophilia with inhibitors

  2010cited by this paper
• Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

  2010cited by this paper
• Advances in hemophilia: experimental aspects and therapy.

  2010cited by this paper
• Safety of recombinant activated factor VII in randomized clinical trials.

  2010cited by this paper
• The North American Immune Tolerance Registry: contributions to the thirty‐year experience with immune tolerance therapy

  2009cited by this paper
• The Role of Tissue Factor and Factor VIIa in Hemostasis

  2009cited by this paper
• Gene Therapy for Hemophilia: Clinical Trials and Technical Tribulations

  2009cited by this paper
• Delivering multiple gene products in the brain from a single adeno-associated virus vector

  2009cited by this paper
• Processing of peptide and hormone precursors at the dibasic cleavage sites

  2009cited by this paper
• Factor VII Deficiency

  2009cited by this paper
• ARFI Ultrasound for In Vivo Hemostasis Assessment Postcardiac Catheterization, Part II: Pilot Clinical Results

  2009cited by this paper
• Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

  2009cited by this paper
• Recent Improvements in the Clinical Treatment of Coagulation Factor Inhibitors

  2009cited by this paper
• Successful treatment of canine hemophilia by continuous expression of canine FVIIa.

  2009cited by this paper
• ARFI Ultrasound for In Vivo Hemostasis Assessment Postcardiac Catheterization, Part I: Preclinical Studies

  2009cited by this paper
• Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.

  2009cited by this paper
• Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

  2009cited by this paper
• Haemophilia care then, now and in the future

  2009cited by this paper
• The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment

  2009cited by this paper
• Gene therapy for haemophilia

  2008cited by this paper
• Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia.

  2008cited by this paper
• Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors.

  2008cited by this paper
• Mechanism of the Ca2+-induced Enhancement of the Intrinsic Factor VIIa Activity*

  2008cited by this paper
• A retrospective study of canine D-dimer concentrations measured using an immunometric "Point-of-Care" test.

  2008cited by this paper
• A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X

  2008cited by this paper
• Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.

  2008cited by this paper
• Laboratory, clinical and therapeutic aspects of acquired hemophilia A.

  2008cited by this paper
• Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.

  2008cited by this paper
• Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A

  2008cited by this paper
• The phenotypic heterogeneity of severe hemophilia.

  2008cited by this paper
• A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

  2007cited by this paper
• Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

  2007cited by this paper
• Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.

  2007cited by this paper
• CD8+ T-cell responses to adeno-associated virus capsid in humans

  2007cited by this paper
• Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

  2006cited by this paper
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

  2006cited by this paper
• Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.

  2006cited by this paper
• Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.

  2006cited by this paper
• Role of Hirudin-like Factor Va Heavy Chain Sequences in Prothrombinase Function*

  2006cited by this paper
• Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.

  2006cited by this paper
• A novel missense mutation responsible for factor VII deficiency in research Beagle colonies

  2006cited by this paper
• Use of the D-dimer assay for diagnosing thromboembolic disease in the dog.

  2005cited by this paper
• Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.

  2005cited by this paper
• Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.

  2005cited by this paper
• Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.

  2005cited by this paper
• New recombinant serotypes of AAV vectors.

  2005cited by this paper
• Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?

  2005cited by this paper
• Expanding hemophilia care in developing countries.

  2005cited by this paper
• Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study.

  2005cited by this paper
• Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

  2004cited by this paper
• Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle.

  2004cited by this paper
• Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

  2004cited by this paper
• Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement.

  2004cited by this paper
• Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

  2004cited by this paper
• FEIBA®: mode of action

  2004cited by this paper
• Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.

  2004cited by this paper
• Why is primary prophylaxis underutilized in the United States?

  2003cited by this paper
• Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

  2003cited by this paper
• Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.

  2003influential reference
• The overall effectiveness of prophylaxis in severe haemophilia

  2003cited by this paper
• Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.

  2003cited by this paper
• Mutagenesis of the γ-Carboxyglutamic Acid Domain of Human Factor VII to Generate Maximum Enhancement of the Membrane Contact Site*

  2003cited by this paper
• Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.

  2002cited by this paper
• Rare coagulation deficiencies

  2002cited by this paper
• Aberrant Splicing and Premature Termination of Transcription of the FVIII Gene as a Cause of Severe Canine Hemophilia A: Similarities with the Intron 22 Inversion Mutation in Human Hemophilia

  2002cited by this paper
• A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.

  2002cited by this paper
• The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion

  2002cited by this paper
• Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene Therapy

  2002cited by this paper
• Experience of prophylaxis treatment in children with severe haemophilia

  2002cited by this paper
• Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia

  2001cited by this paper
• Elevated Function of Blood Clotting Factor VIIa Mutants That Have Enhanced Affinity for Membranes

  2001cited by this paper
• Catheter-related deep venous thrombosis in children with hemophilia.

  2001cited by this paper
• Substitution of Valine for Leucine 305 in Factor VIIa Increases the Intrinsic Enzymatic Activity*

  2001cited by this paper
• Inhibitor Antibodies to Factor VIII and Factor IX: Management

  2000cited by this paper
• The use of central venous catheters (portacaths) in children with Haemophilia

  2000cited by this paper
• Pharmacokinetics of Recombinant Activated Factor VII (rFVIIa)

  2000cited by this paper
• Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.

  2000cited by this paper
• Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

  1999cited by this paper
• Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors

  1998cited by this paper
• Occurrence of hemophilia in the United States

  1998cited by this paper
• When should prophylactic treatment in patients with haemophilia A and B start?— The German experience

  1998cited by this paper
• Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins.

  1997cited by this paper
• Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

  1996cited by this paper
• A deletion mutation causes hemophilia B in Lhasa Apso dogs.

  1996cited by this paper
• Furin/PACE/SPC1: A convertase involved in exocytic and endocytic processing of precursor proteins

  1996cited by this paper
• Effects of hemophilia on articulations of children and adults.

  1996cited by this paper
• Tissue Factor: molecular recognition and cofactor function

  1995cited by this paper
• A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs

  1994cited by this paper
• Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A

  1993cited by this paper
• Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B

  1992cited by this paper
• Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody.

  1990cited by this paper
• Canine hemophilia B resulting from a point mutation with unusual consequences.

  1989cited by this paper
• Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.

  1989cited by this paper
• Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

  1985cited by this paper
• The knee joint in hemophilia.

  1979cited by this paper

• Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction

  2022cites this paper
• Blood Disorders in Patients with Obstructive Jaundice: A Literature Review

  2022cites this paper
• An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics

  2020cites this paper
• Engineering of human albumin for enhanced half-life and transmucosal 1 delivery of protein-based biologics 2

  2020cites this paper
• A Look at the Future Hemophilia A Treatment

  2018cites this paper
• Gene Therapy for Coagulation Disorders.

  2016cites this paper
• Gene Therapy for Coagulation Disorders

  2016cites this paper
• DEVELOPMENT OF COMPETITIVE POTENT DRUG TARGET TO FACTOR VIII IN HAEMOPHILIA

  2012cites this paper